Bottom line
"Sema + Cagri" is a vendor label for semaglutide + cagrilintide mixtures claiming equal masses. The component pairing resembles the genuine CagriSema clinical-development co-formulation, but a vendor product is not thereby CagriSema and must not borrow its identity, evidence, or quality controls. No published study of the observed vendor products was identified.
No established or recommended human dose. Reported amounts below are market observations, not guidance.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Advanced Research Peptides (2026) | Semaglutide, Cagrilintide | 5 / 5 mg | Vendor-declared; identity and contents not independently verified |
| Dosage Peptide (2026) | Semaglutide, Cagrilintide | 10 / 10 mg | Vendor-declared market observation |
| Genetic Peptide (2026) | Semaglutide, Cagrilintide | 5 / 5 or 10 / 10 mg | Vendor-declared market observation |
Equal-mass vendor labels do not establish equivalence to the CagriSema development product, its studied formulation, or any trial exposure.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| Semaglutide | See component monograph; approved-product evidence is product-specific | CagriSema is a distinct development co-formulation, not validation of vendor copies | No evidence identified for the observed vendor products |
| Cagrilintide | See component monograph; development evidence is product-specific | CagriSema is a distinct development co-formulation, not validation of vendor copies | No evidence identified for the observed vendor products |
Combination-specific studies
CagriSema has a documented clinical-development identity, summarized by the higher-quality anchor below. No study identified by this atlas tested the cited vendor products, and no equivalence between those products and CagriSema should be inferred.
Safety and interaction uncertainties
Unknown vendor products cannot inherit the safety, pharmacokinetic, or manufacturing record of a clinical-development product.
Identity, purity, sterility, concentration, excipients, and co-formulation stability are not established by the listings.
Equal mass does not establish pharmaceutical equivalence or bioequivalence.
A fixed mixture complicates attribution of an unexpected effect.
Regulatory and product-quality notes
Semaglutide product approvals do not extend to an unverified semaglutide + cagrilintide vendor blend.
CagriSema is a specific development product name, not a generic label for any product containing the same named components.
Vendor pages are low-quality market observations and do not establish approval, authenticity, or suitability for humans.
Evidence gaps
No evidence of identity or equivalence between vendor products and CagriSema
No independent analytical comparison of the observed listings
No published stability data for the vendor mixtures
No standardized use of the "Sema + Cagri" name
Sources
Advanced Research Peptides. Semaglutide + Cagrilintide market page. https://advancedresearchpep.com/ accessed 2026-08-08.
Dosage Peptide. Semaglutide + Cagrilintide market page. https://dosagepeptide.com/ accessed 2026-08-08.
Genetic Peptide. Sema + Cagri market page. https://geneticpeptide.com/ accessed 2026-08-08.
Wikipedia contributors. Cagrilintide/semaglutide (CagriSema overview and references). https://en.wikipedia.org/wiki/Cagrilintide/semaglutide accessed 2026-08-08.